Table 2.
Characteristics of disease groups at study entry (including laboratory data and assessments of disease activity with clinical scores as appropriate).
| Control group (n = 55) |
Intervention group (n = 55) |
Total (n = 110) |
|
|---|---|---|---|
| RA [n (%)] | 13 (23.6%) | 16 (29.1%) | 29 (26.4%) |
| Rheumatoid factor [% +] | 76.9% | 81.3% | 79.3% |
| ANA [% +] | 46.2% | 50.0% | 48.3% |
| Median CDAI [VAS (range)] | 6 (2–15) | 3 (1–18) | 4,5 (1–18) |
| axSpA [n (%)] | 20 (36.4%) | 16 (29.1%) | 36 (32.7%) |
| HLA-B27 [% +] | 55.0% | 56.3% | 55.6% |
| BASDAI [median (range)] | 3,6 (0.2–8.1) | 3.45 (2.2–6.6) | 3.45 (0.2–8.1) |
| pSpA/PsA [n (%)] | 12 (21.8%) | 12 (21.8%) | 24 (21.8%) |
| HLA-B27 [% +)] | 25.0% | 16.7% | 20.8% |
| BASDAI [median (range)] | 4.2 (2.8–5.2) | 4.1 (0.7–6) | 4.15 (0.7–6) |
| cDAPSA [median (range)] | 6 (0–9) | 8 (1–21) | 6 (0–21) |
| Other inflammatory diagnosis [n (%)] | 8 (14.5%) | 8 (14.5%) | 16 (14.5%) |
| Non-inflammatory diagnosis [n (%)] | 2 (3.60%) | 3 (5.50%) | 5 (4.50%) |
ANA = antinuclear antibodies; axSpA = axial spondyloarthritis; BASDAI = Bath ankylosing spondylitis activity index; CDAI = clinical disease activity index; pSpA = peripheral Spondyloarthritis; PsA = psoriatic arthritis; RA = rheumatoid arthritis; VAS = visual analog scale.